Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,847 articles
Planet Labs Stock Drives Higher After Q4 Beats Estimates
Planet Labs PBC (NYSE:PL) shares drove higher in Thursday's extended trading after the company released its fourth-quarter earnings...
📰
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --
-- Interim systemic lung cancer...
📰
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer...
📰
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated...
📰
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated...
📰
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
REGULATED INFORMATION
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
U.S. Commercialization Off to a Strong Start...
📰
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong...
📰
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
Top Research Reports for Procter & Gamble, UnitedHealth & Wells Fargo
PG faces margin pressure from tariffs and costs, but steady sales and brand strength highlight resilience amid a mixed consumer backdrop.
Tower Semiconductor Rallies On AI Power Wall, Oriole Networks Updates
Tower Semiconductor Ltd (NASDAQ:TSEM) shares are trading sharply higher Thursday afternoon as investors continued to react to a pair of AI-focused...
📰
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a...
📰
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety...
📰
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to...
📰
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179,...
📰
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80...
📰
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative...
📰
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S....
📰
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<ul...
📰
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S....
📰
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety...
📰
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80...
📰
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the...
📰
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
📰
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully...
📰
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully...
📰
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<ul...
📰
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage...
📰
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
Final Data from Phase 2 Expansion...
📰
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage...
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology...
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology...
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for...
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for...
📰
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds...
📰
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly...
📰
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
They aren't just "pandemic stocks."